Efficacy and Safety of SPC1001 in Patients With Essential Hypertension — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Safety of SPC1001 in Patients With Essential Hypertension — Stella

Home/Hypertension, Essential/

View on ClinicalTrials.gov

Recruiting

Back to Hypertension, Essential trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

South Korea

CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea, Seoul

Key details

Phase

Safety & dosing

Sponsor

Shin Poong Pharmaceutical Co. Ltd.

Enrollment target

~252 participants

Started

June 2024

Primary completion

October 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

19 Years – 75 Years

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.